For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
28
views
Article has an altmetric score of 1
46
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      307
      similar
       All similar

      Neuropsychiatric Disease and Treatment (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on all aspects of neuropsychiatric and neurological disorders. Sign up for email alerts here.

      63,741 Monthly downloads/views I 2.989 Impact Factor I 4.5 CiteScore I 1.09 Source Normalized Impact per Paper (SNIP) I 0.744 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          This survey aims to explore the current medical treatment of major depressive disorder (MDD) in China and match its degree with Canadian Network for Mood and Anxiety Treatments (CANMAT).

          Methods

          A total of 3275 patients were recruited from 16 mental health centers and 16 general hospitals in China. Descriptive statistics presented the total number and percentage of drugs, as well as all kinds of treatments.

          Results

          Selective serotonin reuptake inhibitors (SSRIs) accounted for the largest proportion (57.2%), followed by serotonin-noradrenaline reuptake inhibitors (SNRIs) (22.8%) and mirtazapine (7.0%) in the first therapy, while that of SNRIs (53.9%) followed by SSRIs (39.2%) and mirtazapine (9.8%) in the follow-up therapy. An average of 1.85 medications was administered to each MDD patient.

          Conclusion

          SSRIs were the first choice in the first therapy, while the proportion of those drugs decreased during the follow-up therapy and were replaced by SNRIs. Plenty of combined pharmacotherapies were directly selected as the first trial of patients, which was inconsistent with guideline recommendations.

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

          Sidney H Kennedy, Raymond W Lam, Roger McIntyre … (2016)
          The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.
          Article 0 comments Cited 313 times – based on 0 reviews     Review now
          Article has an altmetric score of 197
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The magnitude of and health system responses to the mental health treatment gap in adults in India and China

            Vikram Patel, Shuiyuan Xiao, Hanhui Chen … (2016)
            This Series paper describes the first systematic effort to review the unmet mental health needs of adults in China and India. The evidence shows that contact coverage for the most common mental and substance use disorders is very low. Effective coverage is even lower, even for severe disorders such as psychotic disorders and epilepsy. There are vast variations across the regions of both countries, with the highest treatment gaps in rural regions because of inequities in the distribution of mental health resources, and variable implementation of mental health policies across states and provinces. Human and financial resources for mental health are grossly inadequate with less than 1% of the national health-care budget allocated to mental health in either country. Although China and India have both shown renewed commitment through national programmes for community-oriented mental health care, progress in achieving coverage is far more substantial in China. Improvement of coverage will need to address both supply-side barriers and demand-side barriers related to stigma and varying explanatory models of mental disorders. Sharing tasks with community-based workers in a collaborative stepped-care framework is an approach that is ripe to be scaled up, in particular through integration within national priority health programmes. India and China need to invest in increasing demand for services through active engagement with the community, to strengthen service user leadership and ensure that the content and delivery of mental health programmes are culturally and contextually appropriate.
            Article 0 comments Cited 132 times – based on 0 reviews     Review now
            Article has an altmetric score of 429
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

              Arun V. Ravindran, Lynda G. Balneaves, Guy Faulkner … (2016)
              The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals.
              Article 0 comments Cited 95 times – based on 0 reviews     Review now
              Article has an altmetric score of 133
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Neuropsychiatr Dis Treat
                Journal ID (iso-abbrev): Neuropsychiatr Dis Treat
                Journal ID (publisher-id): ndt
                Title: Neuropsychiatric Disease and Treatment
                Publisher: Dove
                ISSN (Print): 1176-6328
                ISSN (Electronic): 1178-2021
                Publication date (Electronic): 12 April 2023
                Publication date Collection: 2023
                Volume: 19
                Pages: 829-839
                Affiliations
                [1 ]Division of Mood Disorders, Shanghai Hongkou Mental Health Center , Shanghai, People’s Republic of China
                [2 ]Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai JiaoTong University School of Medicine , Shanghai, People’s Republic of China
                [3 ]Clinical Research Center for Mental Health, School of Medicine, Shanghai University , Shanghai, People's Republic of China
                [4 ]Clinical Research Center in Mental Health, Shanghai Yangpu District Mental Health Center, Shanghai University of Medicine & Health Sciences , Shanghai, People's Republic of China
                [5 ]Division of Psychiatry, Shanghai Changning Mental Health Center , Shanghai, People’s Republic of China
                [6 ]New York University , New York, NY, USA
                [7 ]Department of Psychiatry & Affective Disorders Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, People's Republic of China
                [8 ]CAS Center for Excellence in Brain Science and Intelligence Technology , Shanghai, People’s Republic of China
                [9 ]Shanghai Key Laboratory of Psychotic Disorders , Shanghai, People’s Republic of China
                Author notes
                Correspondence: Yiru Fang, Email yirufang@aliyun.com
                [*]

                These authors contributed equally to this work

                Author information
                http://orcid.org/0000-0003-4686-8887
                http://orcid.org/0000-0002-1929-231X
                http://orcid.org/0000-0003-4338-967X
                http://orcid.org/0000-0002-8748-9085
                Article
                Publisher ID: 401359
                DOI: 10.2147/NDT.S401359
                PMC ID: 10106790
                PubMed ID: 37077710
                SO-VID: 0cb67b1b-cc1e-428a-a6f6-c263bc18b5a5
                Copyright © © 2023 Zhu et al.
                License:

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                Date received : 13 December 2022
                Date accepted : 23 March 2023
                Page count
                Figures: 2, Tables: 3, References: 46, Pages: 11
                Funding
                Funded by: The National Key Research and Development Program of China ;
                Funded by: the National Natural Science Foundation of China;
                Funded by: Shanghai Key Medicine Specialties Program;
                Funded by: Shanghai Clinical Research Center for Mental Health;
                Funded by: the Scientific Research Project of Hongkou District Health Commission;
                Funded by: Excellent Talent Training Program of Shanghai Hongkou Mental Health Center;
                The National Key Research and Development Program of China (2016YFC1307100), the National Natural Science Foundation of China (91232719, 81771465, 81930033), Shanghai Key Medicine Specialties Program (ZK2019A06), Shanghai Clinical Research Center for Mental Health (SCRC-MH, 19MC1911100), the Scientific Research Project of Hongkou District Health Commission (2101-03) and Excellent Talent Training Program of Shanghai Hongkou Mental Health Center (2023XKDTR01).
                Categories
                Subject: Original Research

                ScienceOpen disciplines: Neurology
                Keywords: major depressive disorder,chinese,guideline,antidepressants
                Data availability:
                ScienceOpen disciplines: Neurology
                Keywords: major depressive disorder, chinese, guideline, antidepressants

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content307

                See all similar

                Cited by2

                See all cited by

                Most referenced authors436

                See all reference authors